Therapeutic strategies in epithelial ovarian cancer.
Therapeutic strategies in epithelial ovarian cancer.
复制标题
DOI：
10.1186/1756-9966-31-14
复制
发表时间：
2012-02-13
期刊：
影响因子：
--
通讯作者：
Enomoto T
中科院分区：
文献类型：
--
作者：
Kim A;Ueda Y;Naka T;Enomoto T
卵巢癌是最致命的妇科恶性肿瘤。似乎绝大多数看起来是原发的卵巢上皮癌和腹膜癌，实际上是继发于输卵管最远端的伞状组织。上皮性卵巢癌的治疗是基于细胞减灭术和紫杉烷和铂联合化疗的组合。虽然透明细胞型被归类为惰性类型，但众所周知，它对卡铂和紫杉醇方案表现出相对较强的耐药性，因此与浆液性腺癌相比预后较差，特别是在晚期。伊立替康联合顺铂治疗透明细胞腺癌可能有效。卵巢癌预后改善的更大期望与新生物制剂的使用有关。贝伐单抗是治疗卵巢癌研究最多、前景最好的分子靶向药物之一，它是一种针对血管内皮生长因子的单抗。PARP抑制剂是另一种。最近的一些研究表明贝伐单抗对卵巢癌患者的无进展生存期有积极的效果，然而，针对卵巢癌患者的分子靶向药物的研究仍在进行中。
Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway.
登录
查看更多内容
DOI：
10.1097/pas.0b013e3181cf3d79
发表时间：
2010-03
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Kurman RJ;Shih IeM
通讯作者：
Shih IeM
影响因子：
45.3
作者：
Fong, Peter C.;Yap, Timothy A.;Kaye, Stan B.
通讯作者：
Kaye, Stan B.
影响因子：
10.3
作者：
Piccart, MJ;Bertelsen, K;Pecorelli, S
通讯作者：
Pecorelli, S
影响因子：
158.5
作者：
Burger, Robert A.;Brady, Mark F.;Liang, Sharon X.
通讯作者：
Liang, Sharon X.
影响因子：
45.3
作者：
Monk, Bradley J.;Herzog, Thomas J.;Poveda, Andres M.
通讯作者：
Poveda, Andres M.